Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
about
Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment optionsTherapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease.SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics.Gout: An old disease in new perspective - A review.A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.Severe Hypernatraemic Dehydration and Unconsciousness in a Care-Dependent Inpatient Treated with Empagliflozin.A more tubulocentric view of diabetic kidney disease.The NLPR3 inflammasome and obesity-related kidney disease.Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus.Cardioprotective anti-hyperglycaemic medications: a review of clinical trials.Novel avenues for drug discovery in diabetic kidney disease.Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.Impact of obesity on annual medical expenditures and diabetes care in Japanese patients with type 2 diabetes mellitus.Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes.Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study.Keeping the right track in the treatment of patients with type 2 diabetes.Renal fibrosis: Primacy of the proximal tubule.Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases.The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.Metabolic effects of Tofogliflozin are efficiently enhanced with appropriate dietary carbohydrate ratio and are distinct from carbohydrate restriction.Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions.Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus.Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot StudySGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathyHistone Deacetylase Inhibitors and Diabetic Kidney Disease
P2860
Q33864537-60B483D2-5E2C-4C7B-B74C-F11BB36A52D8Q38688345-6AF61CF6-9753-43F5-B930-B5E5E550BB76Q38961637-44740E26-64A3-414E-889B-07016DB9B862Q39126658-A2E5CE2E-4ED2-4D4C-8EF0-A09093B74C2EQ40106739-E2949FAA-F9E5-4C6E-9464-A79C82EABFA2Q41020576-F2AECC5A-BB87-427D-A77E-C3BF0C230F85Q46541426-61A0FFA5-A6E6-48A4-B593-3F2753951621Q47105157-7AE58744-615E-4BEB-85E4-315A43D597F8Q47108081-DF64EF2D-7128-4136-A40D-927E416E3114Q47130640-65ADFE48-A9E0-45DA-962E-F8A660DAC15EQ47214520-39E5286F-92C4-467A-9F29-EDAF9DEED911Q47297477-6CA5FD69-646A-4753-A8E1-D9D10A98678AQ47395215-835E4C39-09C3-4E13-B97B-31E129AFAE88Q47635939-63FB26FE-AA1C-44F3-9946-92446A009A8DQ48131003-50EA9861-AC2D-47D3-9495-C4D19F323D1CQ48141985-F4A1871F-3AE0-42E1-B826-3ACA767DAC82Q48266508-E0CC4B54-9BF7-40AD-AEC6-2F3881D98AF8Q49686849-4B56B4B7-1B19-4C4E-8F10-5CFE71F980FDQ50097164-B0FCB6D1-1F90-476B-A868-D67BAB7A9DAFQ50103024-C0D98127-E18A-4E6B-8100-6008984D2D1FQ51045694-CB7DEF53-E1EE-4176-AE22-A764DF8ACC12Q52665265-50808045-B3A5-4D80-8085-7D1C77CE375DQ52673331-76DB47B6-C96C-4018-869F-E694C4335546Q55053753-9DE76A87-CAFC-412B-BD14-8D0B565D7AF0Q55262124-B7E7CF33-D454-4049-B889-1076C5A1FA81Q57136996-E6337D4A-C77E-4768-A2DE-91A2B66A4D61Q57170120-EDAB4AB7-030F-4AF6-AE63-4B2A08D11063Q58762435-01907F2B-BC41-457B-B268-B886F280052D
P2860
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Targeting renal glucose reabso ...... c effects of SGLT2 inhibition.
@en
Targeting renal glucose reabso ...... c effects of SGLT2 inhibition.
@nl
type
label
Targeting renal glucose reabso ...... c effects of SGLT2 inhibition.
@en
Targeting renal glucose reabso ...... c effects of SGLT2 inhibition.
@nl
prefLabel
Targeting renal glucose reabso ...... c effects of SGLT2 inhibition.
@en
Targeting renal glucose reabso ...... c effects of SGLT2 inhibition.
@nl
P2860
P1433
P1476
Targeting renal glucose reabso ...... ic effects of SGLT2 inhibition
@en
P2093
Scott C Thomson
P2860
P2888
P304
P356
10.1007/S00125-016-4157-3
P577
2016-11-22T00:00:00Z